Rheumatoid Arthritis: Statement Analysis
Statements (a) and (e) are correct; rheumatoid factor is positive in 70-80% of patients, and ESR/CRP are validated tools for monitoring disease activity. Statements (b), (c), and (d) are incorrect based on the characteristic clinical features of rheumatoid arthritis.
Detailed Analysis of Each Statement
Statement (a): Rheumatoid Factor Positivity - CORRECT
Rheumatoid factor is indeed positive in approximately 70-80% of patients with rheumatoid arthritis 1. More specifically, research demonstrates that 65-70% of patients show positive serologic tests for rheumatoid factor 1. This aligns closely with the stated range and represents a well-established diagnostic characteristic, though it's important to recognize that 20-30% of RA patients remain seronegative.
Clinical caveat: RF positivity is not specific to RA—it can occur in other chronic diseases including infective endocarditis, sarcoidosis, leprosy, and hyperglobulinemic conditions 1. Anti-CCP antibodies provide greater specificity when RF is negative 2.
Statement (b): Spinal Involvement - INCORRECT
This statement is partially wrong. RA characteristically affects the cervical spine but NOT the lumbar spine 3, 4. The disease can cause significant cervical spine involvement including atlantoaxial subluxation, pannus formation, and potentially fatal cervical myelopathy 5, 4. However, the lumbar spine and sacroiliac joints are rarely involved in RA 3.
Critical distinction: Cervical spine disease occurs in approximately 19.7% of RA patients with disease duration >5 years 4, and can manifest as anterior atlantoaxial subluxation (most common), vertical subluxation, or subaxial subluxation. This represents a serious complication requiring careful monitoring, as cervical myelopathy can be fatal 5.
Statement (c): Pattern of Joint Involvement - INCORRECT
This statement is fundamentally wrong. RA is characteristically a SYMMETRIC polyarthritis, not asymmetric 3. The disease typically presents with symmetric swelling of small joints, most frequently affecting metacarpophalangeal, proximal interphalangeal, and metatarsophalangeal joints, as well as wrists and knees 3.
Typical presentation patterns:
- Insidious onset with symmetric small joint involvement (most common)
- Acute or subacute onset (25% of cases)
- Palindromic onset (recurrent oligoarthritis episodes)
- Monoarticular presentation (rare)
The distal interphalangeal joints are characteristically spared in RA 3, which helps distinguish it from osteoarthritis.
Statement (d): Extra-articular Manifestations - INCORRECT
Serositis is NOT the most common extra-articular manifestation of RA. While extra-articular manifestations are extremely common (present in 93% of patients) 6, the most frequent include:
- Rheumatoid nodules (most common)
- Hematologic abnormalities
- Vasculitis
- Felty's syndrome
- Visceral involvement 3
Extra-articular manifestations are strongly associated with sustained systemic inflammation, particularly elevated ESR 6, and correlate with disease severity, disability, and mortality risk.
Statement (e): ESR and CRP for Monitoring - CORRECT
ESR and CRP are validated, recommended tools for monitoring disease activity in RA 7, 8, 9. The ACR explicitly recommends their use as components of validated disease activity measures including DAS28-ESR, DAS28-CRP, and SDAI 7.
Key evidence supporting their use:
- Both markers accurately reflect disease activity and are sensitive to change 7
- ESR and CRP are incorporated into multiple validated composite measures (DAS28, SDAI) that facilitate "treat-to-target" strategies 7, 9
- Serial measurements provide reliable discrimination between symptomatic relief and profound disease modification 10
- Persistently elevated CRP and ESR correlate with radiographic progression and erosive damage 10
Important nuances:
- CRP is generally superior to ESR for measuring acute inflammation, as ESR is influenced by non-inflammatory factors including immunoglobulins, rheumatoid factor, and hemoglobin 11, 12
- Discordance between ESR and CRP occurs in 27.3% of measurements 12; when discordant, CRP better reflects true disease activity 11
- Both markers provide complementary information—ESR may capture general disease severity while CRP more specifically reflects inflammation 11, 12
- Biologic agents targeting specific cytokines can differentially affect ESR and CRP, potentially deflating composite scores 7
Monitoring frequency: Active disease requires assessment every 1-3 months, with treatment adjustment if no improvement occurs within 3 months or target not achieved within 6 months 9.
Summary
Correct statements: (a) and (e)
Incorrect statements: (b), (c), and (d)